Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behcet's disease responding to infliximab

被引:21
作者
Coulter, Ian [1 ]
Huda, Saif [2 ]
Baborie, Atik [3 ]
Jacob, Anu [2 ]
机构
[1] Walton Ctr NHS Fdn Trust, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England
[2] Walton Ctr NHS Fdn Trust, Dept Neurol, Liverpool L9 7LJ, Merseyside, England
[3] Walton Ctr NHS Fdn Trust, Dept Neuropathol, Liverpool L9 7LJ, Merseyside, England
关键词
Behcet's disease; Infliximab; Myelitis; Spinal cord; Paraparesis; CLINICAL CHARACTERISTICS; CASE-SERIES; INVOLVEMENT;
D O I
10.1179/2045772311Y.0000000050
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Context: Isolated involvement of the spinal cord is an uncommon presentation of neuro-Behcet's disease (NBD) and it is associated with a poor prognosis for functional recovery. Method: A case report of an 18-year-old Turkish man who presented with a progressive paraparesis and bladder dysfunction secondary to a longitudinally extensive transverse myelitis as the sole presentation of NBD. Findings: Examination revealed a spastic paraparesis and a T7 sensory level. Magnetic resonance imaging revealed multiple enhancing lesions throughout the thoracic cord and cerebrospinal fluid showed intense neutrophilia. On further enquiry a family history of Behcet's disease was elicited. The patient subsequently reported a history of recurrent oral ulceration and intermittent occular inflammation. A diagnosis of NBD was made and intravenous high-dose steroids commenced with poor response. In view of the poor prognosis for functional recovery associated with spinal NBD the patient was treated with infliximab, an anti-tumour necrosis factor-alpha monoclonal antibody, leading to excellent recovery of function. Conclusion/clinical relevance: Early treatment with infliximab may facilitate a favourable functional recovery and should be considered in cases of NBD with spinal cord involvement.
引用
收藏
页码:122 / 124
页数:3
相关论文
共 15 条
[1]   Clinical patterns of neurological involvement in Behcet's disease:: evaluation of 200 patients [J].
Akman-Demir, G ;
Serdaroglu, P ;
Tasçi, B .
BRAIN, 1999, 122 :2171-2181
[2]  
Al-araji A, 2010, CLIN EXP RHEUMATOL, V28, pS119
[3]   Neuro-Behcet's disease: epidemiology, clinical characteristics, and management [J].
Al-Araji, Adnan ;
Kidd, Desmond P. .
LANCET NEUROLOGY, 2009, 8 (02) :192-204
[4]   Anti-TNF Agents for Behcet's Disease: Analysis of Published Data on 369 Patients [J].
Arida, Aikaterini ;
Fragiadaki, Kalliopi ;
Giavri, Eirini ;
Sfikakis, Petros P. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (01) :61-70
[5]  
Behçet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
[6]   Infliximab for patients with neuro-Behcet's disease: case series and literature review [J].
Borhani Haghighi, Afshin ;
Safari, Anahid ;
Nazarinia, Mohammad Ali ;
Habibagahi, Zahra ;
Shenavandeh, Saeedeh .
CLINICAL RHEUMATOLOGY, 2011, 30 (07) :1007-1012
[7]   Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease [J].
De Cassan, Chiara ;
De Vroey, Benedicte ;
Dussault, Catherine ;
Hachulla, Eric ;
Buche, Sebastien ;
Colombel, Jean-Frederic .
JOURNAL OF CROHNS & COLITIS, 2011, 5 (04) :364-368
[8]   The long-term mortality and morbidity of Behcet syndrome - A 2-decade outcome survey of 387 patients followed at a dedicated center [J].
Kural-Seyahi, E ;
Fresko, I ;
Seyahi, N ;
Ozyazgan, Y ;
Mat, C ;
Hamuryudan, V ;
Yurdakul, S ;
Yazici, H .
MEDICINE, 2003, 82 (01) :60-76
[9]   Multifocal myelitis in Behcet's disease [J].
Moskau, S ;
Urbach, H ;
Hartmann, A ;
Schmidt, S .
NEUROLOGY, 2003, 60 (03) :517-517
[10]   Adalimumab (Humira™): A promising monoclonal anti-tumor necrosis factor alpha in ophthalmology [J].
Neri P. ;
Zucchi M. ;
Allegri P. ;
Lettieri M. ;
Mariotti C. ;
Giovannini A. .
International Ophthalmology, 2011, 31 (2) :165-173